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ABSTRACT 
Background/Aims: Surgical resection is a radical treatment option for pancreatic 
carcinoma (PC); however, it is still difficult to cure and patient prognosis is poor at this 
stage.  
Methodology: We examined the demographics, surgical records, and outcome in 64 
patients with hilar PC undergoing surgical resection.  
Results: Pancreatoduodenectomy (PD) was carried out in 48 patients, distal 
pancreatectomy (DP) in 14 and total pancreatectomy in two. Postoperative complications 
were observed in 18 patients (28%) but no hospital death. All stage I patients showed 
carcinoma in-situ of intraductal papillary mucinous carcinoma (IPMC). Postoperative 
adjuvant chemotherapy was performed in 15 patients (23%) using gemcitabine or S-1. 
Cancer recurrence was observed in 36 patients (56%) and 31 died of carcinoma.  The 
5-year cancer-free and overall survival rate was 12% and 14%, respectively. These 
survival rates were poor according to stage of tumor and survival, between Stage III, IVa 
and IVb were similar.  CA19-9 level, morphological type, T category, lymph node 
metastasis, extrapancreatic nerve plexus invasion, retropancreatic tissue invasion, distal 
bile duct invasion, duodenal invasion and arterial system invasion were significant poor 
prognostic factors; however, portal vein system invasion was not significantly associated 
with prognosis. Cancer infiltration at bile duct cut-end and dissected peripancreatic tissue 
margin and presence of residual tumor showed a poor prognosis. Surgical prognosis in 
only non-invasive IPMC was satisfactory. 
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Conclusions: Radically extended surgical resection is necessary and newly effective 
adjuvant chemotherapy is a promising modality to improve patient survival in PC 
patients. 
KEYWORDS: pancreatoduodenectomy, distal pancreatectomy, pancreatic carcinoma, 
curability 
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ABBREVIATIONS: Pancreatic carcinomas (PC), pancreatoduodenectomy (PD), distal 
pancreatectomy (DP),  
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INTRODUCTION 
Surgical resection is the only curable treatment for pancreatic carcinomas (PC) 
although the resection rate is still low at this stage (1). Concurrent extended pancreatic 
resection is often necessary to accomplish complete (R0) resections, which may improve 
patient prognosis (1-5). Resection of the nerve plexus around the pancreas or combined 
resection of portal vein maintains surgical curability in PC patients (6, 7). On the other 
hand, physical stress in patients is relatively high and postoperative morbidity and 
mortality rates are still not low (8). Therefore, the indication of operation for PC should 
be carefully decided. In recent years, chemotherapy for PC has become effective and 
patient prognosis has improved (9). In patients who underwent surgical resection, 
adjuvant chemotherapy showed a survival benefit (10). Thus, treatment results for PC 
have been recently changed. To estimate the present status regarding surgical treatments 
for PC at our institute, we examined our series of PC in 64 patients at a Japanese single 




We experienced 111 patients with PC administrated in the Division of Surgical 
Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate 
School of Biomedical Sciences (NUGSBS) between 1994 and 2008. In these patients, 64 
patients (58%) who could undergo surgical resections were analyzed in the present study. 
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In another 47 patients, highly advanced PC such as a local extension to the 
supra-mesenteric artery (SMA), peritoneal dissemination or distant metastasis were 
found and radical operation was avoided before or during operation. The study design 
was approved by the Human Ethics Review Board of our institution.  Informed consent 
for data collection was obtained by each patient during this period. Anesthetic and patient 
data were retrieved in the NUGSBS database. Tumor stage and curability was followed 
by the Classification of Pancreatic Carcinoma (11). 
 
Operative procedures and follow-up 
Pancreaticoduodenectomy (PD) is a basic surgical option for PC located in the 
pancreatic head and distal pancreatectomy (DP) is selected for PC in the body or tail of 
pancreas. In cases where PC extended widely, total pancreatectomy was selected in 2 
cases. Lymphadenectomy was basically performed in Group 2 lymph nodes and lymph 
nodes at the para-aortic lesion (station number 16a2 and 16b1). Extrapancreatic nerve 
plexus was also resected in half of the cases around the SMA. In case of PD, Child's 
intestinal reconstruction with end-to-side anastomosis of pancreatojejunostomy or 
pancreato-gastrostomy was routinely selected. In case of DP, pancreatic stump was closed 
by suturing in a fish mouth shape. 
 In case of tumor involvement to the portal vein or supra-mesenteric vein (SMV), 
splenic artery or vein, and common hepatic artery, radical operation was considered. 
When combined resection of the portal vein or SMV was performed, end-to-end 
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anastomosis  of vessels or graft interposition using expanded polytetrafluoroethylene 
(ePTFE; Gore-Tex®,W. L. Gore & Associates, Inc., Newark, DE )  artificial blood vessel 
was applied. In case vascular anastomosis was expected for more than 30 minutes, we 
used a passive veno-venous bypass from the SMV to umbilical portal vein of the liver 
using an antithrombogenic Anthron® bypass tube (Toray Industries, Tokyo, Japan). 
When arterial blood flow was preserved via SMA, gastroduodenal artery and the proper 
hepatic artery, the combined resection of the common hepatic artery or celiac axis with 
distal pancreatectomy is considered to be resected. Fibrin glue was used to prevent 
pancreatic fistula. 
After discharge from the hospital, the patient status, laboratory data, and disease 
recurrence were carefully checked every 3 months. The minimum follow-up period after 
operation was 12 months in the present study. 
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RESULTS 
        Patients included 39 men and 25 women with a mean age of 68.5 ± 9.6 years (± SD, 
range, 47-87 years). These patients underwent PD in 48 patients (pylorus preserving PD 
in 18, PD in 25 and subtotal stomach-preserving PD in 5), DP in 14 and total 
pancreatectomy in two. Postoperative complications were observed in 18 patients (28%) 
including pancreatic fistula in 3, delayed gastric empty in 8, bile leak in one, biliary 
obstruction in 2, chyle fistula in one, liver abscess in one, pneumonia in one, and 
obstruction of gastro-jejunostomy in one. Hospital death was not observed.  
Stage of tumor was I in 5, II in 13, III in 12, IVa in 21 and IVb in 13. All patients with 
stage I showed carcinoma in-situ of intraductal papillary mucinous neoplasm (IPMN). 
Positive cancer margin at pancreatic cut-end margin was observed in 4 patients (6%), at 
bile duct cut-end margin in one (2%), and at dissected peripancreatic tissue margin in 7 
(11%). Postoperative adjuvant chemotherapy was performed in 15 patients (23%) 
including use of 1g/m2 of gemcitabine (Gemzar; Eli Lilly and Co., Indianapolis, IN) in 10 
and 80mg of S-1 (TS-1®; Taiho pharmaceutical Co, Ltd., Tokyo, Japan) in 5.  
       Postoperative cancer recurrence was observed in 36 patients (56%), which included 
peritonitis carcinomatosa in 9 patients, liver metastasis in 20, local recurrence in 5, and 
lung metastasis in 2. Thirty-five patients (55%) died after operation, which included 
cancer-related death in 31 and other disease in 4.  
     Figures 1 and 2 show the cancer-free and overall survival after operation. Mean 
cancer-free survival time was 22 months, and 3- and 5-year cancer-free survival rate was 
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22% and 12%, respectively. Mean overall survival time was 29 months, and 3- and 5-year 
overall survival rate was 25% and 14%, respectively. By comparison with tumor stage, 3- 
and 5-year tumor-free survivals were significantly different between Stages (80% and 
80% in I, 33% and 33% in II, 9% and 0% in III, 13% and 6% in IVa and 9% and  0% in 
IVb, p=0.009). Mean cancer-free survival time was significantly correlated with Stages 
(76 months in I, 32 in II, 11 in III, 13 in IVa and 10 in IVb, respectively). By comparison 
with tumor stage, 5-year cancer-related overall survival was also significantly different 
between stages (100% in I, 63% in II, 17% in III, 26% in IVa and 10% in IVb, p=0.005). 
Mean cancer-related overall survival time was significantly correlated with Stages (206 
months in I, 55 in II, 22 in III, 23 in IVa and 13 in IVb, respectively). Between stage III, 
IVa and IVb, postoperative survival was similar. Table 1 shows the relationship between 
overall 5-year survival rate and clinical parameters. CA19-9 level was significantly 
related to poor survival rate (p<0.05). Cystic or ductectatic type tumor showed better 
survival rate compared to nodular or infiltrative type (p<0.05). Table 2 shows the  
relationship between overall 5-year survival rate and pathological parameters. Higher T 
category, lymph node metastasis, non-invasive IPMC, extrapancreatic nerve plexus 
invasion, retropancreatic tissue invasion, distal bile duct invasion, duodenal invasion and 
arterial system invasion were significantly associated with poor survival. Portal vein 
system invasion was not significantly associated with prognosis. Cancer infiltration at 
bile duct cut-end margin and dissected peripancreatic tissue margin showed poor 
prognosis. By comparison between classification of lymph node dissection, degree of 
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dissection significantly correlated with poor prognosis. Presence of residual tumor tended 
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DISCUSSION 
Recently, aggressive surgical exploration with or without vascular resections for PC 
is usually performed and survival has been remarkably improved (1-7, 12). As the 
techniques and perioperative management have remarkably improved, we have actively 
performed extended resections for complete tumor resections (R0) during the last 15 
years as well. Based on previous reports, the usefulness of R0 resection for PC has been 
reported in recent years (1-5).  
In our series, the mean age of PC patients was similar to that in other reports (11, 12) 
and, as a modern trend, many patients were older than 70 years. Other reports showed that 
elderly patients over 80 years can also undergo this major surgery if the patient has no 
serious complications and a strong performance status (13). Our series included 7 patients 
over 80 years, and they had good operative courses. With respect to general conditions 
before surgery, only a few patients did not undergo radical operation due to severe 
chronic respiratory disorder using home oxygen treatment, accompanying multi-organ 
dysfunctions or senile dementia. Two patients undergoing hemodialysis may have had PD 
with good outcomes.  Preoperative examinations for PC and its extension have been 
dramatically improved such as advanced computed tomography or magnetic resonance 
image, endoscopic retrograde pancreatography and associated useful diagnostic tools 
(intraductal ultrasonography and biopsy), endoscopic ultrasonography and associated 
fine needle aspiration (FNA) biopsy (14, 15). Diagnosis of lymph node metastasis by this 
examination is possible at this stage (15). At our institute, combinations of these imaging 
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modalities have been applied; however, the precise evaluation of cancer extension or 
node metastasis is still difficult before operation at this stage. In the next step, FNA or 
enhanced ultrasonography using a perfluorobutane microbubble agent (SonozoidTM, GE 
Healthcare AS, Oslo, Norway) must be applied to determine the preoperative diagnosis 
(16). Preoperative diagnosis of node metastasis at the para-aortic region, which may be 
considered to be a contraindication of surgery, is still difficult by conventional modalities 
(17). Based on our experiences, positive predictive rate or sensitivity of diagnosis of 
para-aortic node metastasis are also low (data not published yet). Positron emission 
tomography or FNA may improve accuracy (18). 
 Although resectability of PC has been as improved described above, advanced 
carcinomas were still found at laparotomy, and 5 patients were inoperable at the time of 
laparotomy due to locally advanced tumor invading SMA, peritoneal carcinomatosis or 
tiny liver metastasis, despite the detailed preoperative image examinations in our series. 
At this stage, extended pancreatectomy might be predominantly performed in Japan 
because only surgical exploration in the surrounding tissues or nodes can accomplish 
high curability (2, 5, 6). In our series, most cases underwent PD including PPPD and DP 
with D2 lymphadenectomy. Complete lymphadenectomy at station number 162a and 
16b1 are considered to be necessary because of a high rate of node metastasis (19). 
Combined resections of the portal vein or SMV were aggressively performed to 
accomplish R0 resection, as in other reports (5, 12, 20). Regarding combined resection of 
SMA, indication of radical operation is still controversial and, therefore, we did not 
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perform this operation. However, if the resected area was short and anastomosis is 
expected to be easy, combined resection of SMA or other major arteries would be 
considered in selected patients. Amano et al recently showed good results concerning this 
procedure (21). Morbidity after pancreatic resections in PC was not high in our series and 
we have not experienced mortality yet. In PC patients, the pancreas accompanied chronic 
pancreatitis and developed a hard architecture by fibrosis and, therefore, the prevalence 
of pancreatic fistula was lower than that in soft pancreas in other diseases (22).  
With respect to stage of tumor, most PC patients except non-invasive IPMC showed 
advanced stages, which led to a poor prognosis in general. Furthermore, the dissected 
margin was positive at a relatively higher rate than the other cut-end margin. Other 
reports showed that R1 or R2 resection was not rare (23) in surgery of PC and cancer 
margin positivity might not always be related to longer survival (24). Waraya et al. (25) 
reported that the dissected peripancreatic margin was  a powerful prognostic factor and, 
therefore, an 11%  positive margin rate is an important problem to be solved in the next 
step. Postoperative adjuvant chemotherapy is a recent trend in patients with advanced PC 
beyond Stage III at our institute because the efficacy of adjuvant chemotherapy using 
gemcitabine or other combination chemotherapy has been clarified recently (10, 26, 27).  
The recurrence rate was also high and that in invasive ductal PC except IPNC was 
increased to 78% in our series, as well as in previous reports (28). We examined survival 
results and associated parameters in our series. The five year-survival in the present study 
was still low regardless of improvement of surgical techniques or perioperative 
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management, which was lower than that in previous reports (1-7, 29). As described above, 
the rate of dissected margin positive was not low and adjuvant chemotherapy has just 
been started recently. To improve the patients’ prognoses, we attempted to perform more 
extensive surgery to resect surrounding tissues. Further long-term follow-up with 
adjuvant chemotherapy is necessary, using promising drugs such as S-1 or cisplatin 
combined with novel chemotherapies (26, 27). Hirata et al. stressed the significance of 
the Japanese stage of PC to reflect patient survival after surgery, and our present series 
showed similar results (20). 
By clinical and histological examinations, serum CA19-9 level was a predictive 
marker for postoperative prognosis (25). In the present series, the median cut-off level of 
85U/ml was applied and survival rates were increased according to increased level of 
CA19-9. To establish an adequate predictive value, receiver operating characteristics 
(ROC) analysis should be examined in a larger number of subjects in future studies. 
Changes of CA19-9 after surgery may be a useful follow-up marker (30). Cystic type or 
ductectatic type is a typical macroscopic finding of IPMN (31) and this type showed good 
outcomes as well as pathological diagnosis. Non-invasive IPMC is a proper indication for 
radical operation expecting long-term survival (32). However, invasive PC derived from 
IPMC showed a poor prognosis as well as invasive ductal carcinomas in our previous and 
present reports (33, 34). IPMC invading surrounding tissues or major vessels needs 
similar operations or adjuvant treatment to those in ordinary invasive PC. Various 
common predictive parameters in the digestive tract carcinomas were also associated 
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with poor outcomes in PC patients who underwent resection at our institute. Interestingly, 
invasions of the portal vein, SMV and splenic vein were not significantly associated with 
survival in these parameters. As described above, combined resection of these veins with 
pancreatic tissue was aggressively performed and the significance of this procedure was 
indicated as well as previous reports (2, 5, 12, 20). As described above, the dissected 
peripancreatic tissue margin and presence of residual tumor must be avoided to improve 
survivals and, therefore, extended pancreatectomy is still necessary. 
In conclusion, aggressive surgical pancreatectomy was performed in 64 patients 
with pancreatic carcinomas including IPMC at a single cancer center over the past 15 
years. Radical operation including combined resections of the portal system vein could be 
safely performed in many cases. Although results in only non-invasive IPMC were 
satisfactory, advanced invasive PC still showed a poor prognosis. Extended surgical 
resection to overcome R0 or cancer negative-margin is necessary as a curative treatment 
and, furthermore, newly effective adjuvant chemotherapy will be promising to improve 
patient survival in PC patients with poor prognostic factors.  
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Table 1. Comparison between overall 5-year survival after resection and clinical, 
macroscopic parameters and postoperative chemotherapy 




   ≤10* 
   >10 
CA19-9 (U/ml) 
  ≤85* 
   >85 
Location of carcinoma 
   Head 
   Body, Tail 
Macroscopic type# 
   Cystic 
   Ductectatic 
   Nodular 
   Infiltrative 
Adjuvant chemotherapy 
   No 


































*; median value 
#; findings according to the Classification of Pancreatic Carcinoma (11) 
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Table 2. Comparison between overall 5-year survival after resection and pathological 
parameters 




    1 
    2 
    3 
    4 
Lymph node metastases# 
    0 
    1 
    2 
    Station number 16a2 or 16b1 
Histological differentiation or type# 
    Well differentiated adenocarcinoma 
  Moderately 
  Poorly 
  Non-invasive IPMC* 
 Extrapancreatic nerve plexus invasion 
  Absent 
  Present 
Serosal invasion# 
  Absent 
  Present 
Retropancreatic tissue invasion# 
  Absent 
  Present 
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  Present 
Duodenal invasion# 
  Absent 
  Present 
Portal venous system invasion# 
  Absent 
  Present 
Arterial system invasion# 
  Absent 
  Present 
Pancreatic cut-end margin# 
  No 
  Cancer infiltration present 
Bile duct cut-end margin# 
  No 
  Cancer infiltration present 
Dissected peripancreatic tissue margin# 
  No 
  Cancer infiltration present 
Classification of lymph node dissection# 
   D1 
   D2 
   D3 
Residual tumor 
  No 
  Microscopic 






















































*; intraductal papillary mucinous carcinoma  
#; findings according to the Classification of Pancreatic Carcinoma (11) 
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Figure legend 
Figure 1. Cumulative cancer-free (a) and overall (b) survival after hepatectomy. 
 
Figure 2. Comparison between stages of tumor and cumulative cancer-free (a) and 
overall (b) survival after hepatectomy. 
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